Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with d...

Full description

Bibliographic Details
Main Authors: Takahiro Kumode, Shinya Rai, Hirokazu Tanaka, J. Luis Espinoza, Hiroaki Kakutani, Yosaku Watatani, Shuji Minamoto, Yasuhiro Taniguchi, Shoko Nakayama, Yasuyoshi Morita, Takashi Ashida, Itaru Matsumura
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Leukemia Research Reports
Subjects:
Myeloid sarcoma
Acute myeloid leukemia
FLT3-ITD
Gilteritinib
Online Access:http://www.sciencedirect.com/science/article/pii/S221304892030025X
Description
Summary:We report a case with extramedullary tumors affecting the supraclavicular region that presented as a relapse of acute myeloid leukemia (AML) with FLT3-ITD mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Treatment with gilteritinib resulted in remarkable response with disappearance of both the medullary and extramedullary tumors. Subsequently, a 2nd allo-HSCT was performed in an attempt to cure his AML and complete molecular response has been sustained with gilteritinib resumption without worsening GVHD. Targeted therapy with gilteritinib for medullary and extramedullary relapse of FLT3-ITD AML could be effective and suitable as a bridging therapy for allo-HSCT.
ISSN:2213-0489

Similar Items